Participants from the Brain Research Center Amsterdam participated in the research
Amsterdam, October 22 – Brain Research Center is pleased that the American biotech company Biogen has submitted a drug that slows down Alzheimer’s for approval to market. The drug was also tested on participants at Brain Research Center in Amsterdam last year. It is exceptional that a drug that slows down Alzheimer’s is submitted for approval.
Or Aducanumab, Whether the medicine, as it is called, actually becomes available on the market depends on the FDA (Federal Drug Administration), which now needs to grant permission. In order to be able to market it in the Netherlands as well, approval from the EMA (European Medicines Agency) or the College for the Evaluation of Medicinal Products will be required. Before a medicine can be placed on the market, there is still some time involved.
Important breakthrough
,,This is big news,’says Niels Prins, director of the Brain Research Center.,For this purpose, the research center was established. We test promising drugs against Alzheimer’s, in order to eventually make them available to patients. Our mission is to eliminate Alzheimer’s from the world. And this is a very important step. This way, the solution gets ever closer..’’
According to Prince, the drug is suitable for people in the early stages of Alzheimer's. "It is administered by infusion. The drug removes the abnormal Alzheimer protein amyloid beta from the brain.".
34 participants in Amsterdam
The research ran from May 2016 to March 2019 at various research centers around the world, including the Brain Research Center. In Amsterdam, 34 patients were treated. In total, worldwide, there are nearly 3,300 people affected.
In March, the study was initially discontinued by Biogen, because based on a smaller data set it was expected that it would not achieve the desired effect. Recently, however, Biogen analyzed a larger data set and found that there was indeed a positive effect. Based on this, it has now been decided to request permission to market the drug.
Here is the link to the press release from Biogen: http://investors.biogen.com/news-releases/news-release-details/biogen-plans-regulatory-filing-aducanumab-alzheimers-disease
Watch the broadcast of EenVandaag via this link: https://www.npostart.nl/eenvandaag/23-10-2019/AT_2115222
Watch the broadcast via this link on Pauw: https://www.npostart.nl/pauw/23-10-2019/BV_101394513
Read the AD press release here: https://www.ad.nl/binnenland/alzheimer-medicijn-lijkt-aan-te-slaan-dit-is-een-mega-stap~ad61e87e/
We are very proud of all the participants who are taking part in scientific research at the Brain Research Center to find a cure for Alzheimer's disease. See here the story of two participants who participated in the Biogen study at our center:
https://www.rtl.nl/video/fdfa0cea-d6a4-4ac6-a833-906da739dce6/